ArticleEuropean urology2022

First-in-human Intravesical Delivery of Pembrolizumab Identifies Immune Activation in Bladder Cancer Unresponsive to Bacillus Calmette-Guérin.

Khyati Meghani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.